Associate Professor Medical Oncology presso Humanitas University - Head of Head and Neck Medical Oncology presso IRCCS Humanitas Cancer Center Milan
Just released on Jama, Nov 28. Opinion on the phase III randomized trial of chemo-immunotherapy vs chemotherapy in first-line rec/met nasopharyngeal cancer (JUPITER-02). Overall, 37% reduction of risk of death at 3 years. To be discussed: - the lack of mainteinance therapy in chemotherapy only arm - the importance of EBV DNA dynamic - no role for PD-L1 expression as predictive factor - less evidence in de novo metastatic pts - applicability in non-endemic settings An important step in the treatment of NPC cancer pts!